Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors
December 21 2023 - 9:21AM
Business Wire
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven
precision cardiovascular medicine company, today announced the
appointment of Paul Burton, J.D., MBA to its Board of Directors as
an Independent Director. Mr. Burton will Chair the Nominating and
Corporate Governance Committee and will also serve as a member of
the Audit Committee.
Mr. Burton is the Managing Partner at 2Flo Ventures, an
early-stage healthcare investor and startup studio focused on
accelerating health equity. He is also the CEO of Akan Biosciences,
a clinical-stage biotech company, and runs an advisory firm working
closely with healthcare growth companies. Mr. Burton brings over 20
years of experience in medical technology innovation, corporate
finance, and shaping the strategy and operations of growth-stage
companies.
Before 2Flo Ventures, Mr. Burton was CEO of several
venture-backed companies developing novel therapeutics. He began
his career in investment banking at Citigroup, executing over $14
billion in M&A and financing transactions. Mr. Burton holds
J.D. and MBA degrees from the University of Illinois
Urbana-Champaign. Over the years, he has helped raise more than $6
billion for more than 20 companies. He has particular expertise in
FDA navigation for companies building novel therapeutics and
medical technologies.
"We are thrilled to welcome Paul to Cardio Diagnostics’ Board of
Directors," said CEO and Co-Founder Meesha Dogan, PhD. "His breadth
of expertise and established track record spanning healthcare
investing, growth strategy, corporate transactions, and operating
biotechnology companies will be invaluable. Paul shares our vision
of using advanced diagnostics for more personalized cardiovascular
care and we look forward to leveraging his insights and expertise
to grow Cardio Diagnostics’ footprint towards becoming the new
standard of cardiovascular care."
"I am thrilled to join the Cardio Diagnostics board to help
drive the next wave of cardiovascular innovation," said Paul
Burton, J.D., MBA, Managing Partner at 2Flo Ventures. "With its
groundbreaking AI-enabled technology, Cardio has enormous potential
to transform the detection, management and prevention of heart
disease. The company’s progress has been impressive, and I look
forward to collaborating closely with Cardio's exceptional
leadership team to help accelerate the company’s growth."
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered
precision cardiovascular medicine company that makes cardiovascular
disease prevention, detection, and management more accessible,
personalized, and precise. The Company was formed to further
develop and commercialize clinical tests by leveraging a
proprietary Artificial Intelligence (AI)-driven Integrated
Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular
disease to become one of the leading medical technology companies
for improving prevention, detection, and treatment of
cardiovascular disease. For more information, please visit
www.cardiodiagnosticsinc.com.
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act of 1995. When used in this
press release, the words or phrases “will”, "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," “goal,” or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include but are not limited to, our ability
to successfully execute our growth strategy, changes in laws or
regulations, economic conditions, dependence on management,
dilution to stockholders, lack of capital, the effects of rapid
growth upon the Company and the ability of management to
effectively respond to the growth and demand for products and
services of the Company, newly developing technologies, the
Company’s ability to compete, regulatory matters, protection of
technology, the effects of competition and the ability of the
Company to obtain future financing. An extensive list of factors
that can affect future results are discussed in the Current Report
on Form 10-K for the period ended December 31, 2022 and Forms 10-Q
for the period ended March 31, 2023 and September 30, 2023 under
the heading “Risk Factors” in Part I, Item IA thereof, and other
documents filed from time to time with the Securities and Exchange
Commission. Such factors could materially adversely affect the
Company's financial performance and could cause the Company's
actual results for future periods to differ materially from any
opinions or statements expressed within this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231221297769/en/
Investors: Gene Mannheimer Investor Relations
855-226-9991 investors@cardiodiagnosticsinc.com
Media & Public Relations: Khullani Abdullahi
pr@cardiodiagnosticsinc.com
Cardio Diagnostics (NASDAQ:CDIO)
Historical Stock Chart
From Apr 2024 to May 2024
Cardio Diagnostics (NASDAQ:CDIO)
Historical Stock Chart
From May 2023 to May 2024